ImageneBio, Inc.
IMAHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. At a $47.9M market cap, ImageneBio, Inc. ranks as a micro-cap company within healthcare. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Market Cap
$47.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-0.98
EPS (TTM)
$-4.22
EPS (Fwd)
$-4.31
ROE
-82.7%
ROA
-43.1%
Cash
$136.2M
Total Debt
$1.9M
Free CF
-$23.2M
52W Change
-47.3%
Annual Financials
Cash vs Debt
Where IMA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IMA finished 26.34% below its 150-day moving average ($5.43) and 30.43% below its 200-day moving average ($5.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMA overbought or oversold?
At the October 20, 2026 close, IMA's RSI(14) was 17.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $136.2M in cash and $1.9M in debt, IMA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$23.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -82.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $8.0M (2023) to $800K (2025), a 90% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ImageneBio, Inc. and its sector.